Genprex shares are trading lower. The company announced updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials for lung cancer and ceased enrollment in its Acclaim-2 clinical trial due to patient recruitment difficulties.
Portfolio Pulse from Benzinga Newsdesk
Genprex shares are trading lower following updates on its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials for lung cancer, and the cessation of enrollment in its Acclaim-2 clinical trial due to patient recruitment difficulties.
August 14, 2024 | 7:18 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Genprex shares are trading lower after the company announced updates on its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials for lung cancer and ceased enrollment in its Acclaim-2 clinical trial due to patient recruitment difficulties.
The cessation of enrollment in the Acclaim-2 trial due to patient recruitment difficulties is a negative development, likely causing investor concern. Updates on Acclaim-1 and Acclaim-3 trials may not have been sufficient to offset the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100